bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Authors: Lamoureux Audrey-Anne , Fisher Michael J. , Lemelle Lauriane , Pfaff Elke , Amir-Yazdani Pouneh , Kramm Christof , De Wilde Bram , Kazanowska Bernarda , Hutter Caroline , Pfister Stefan M. , Sturm Dominik , Jones David T.W. , Orbach Daniel , Pierron Gaëlle , Raskin Scott , Drilon Alexander , Diamond Eli L. , Harada Guilherme , Zapotocky Michal , Zamecnik Josef , Krskova Lenka , Ellezam Benjamin , Weil Alexander G. , Venne Dominic , Barritault Marc , Leblond Pierre , Coltin Hallie , Hammad Rawan , Tabori Uri , Hawkins Cynthia , Hansford Jordan R. , Meyran Deborah , Erker Craig , McFadden Kathryn , Sato Mariko , Gottardo Nicholas G. , Dholaria Hetal , Nørøxe Dorte Schou , Goto Hiroaki , Ziegler David S. , Lin Frank Y. , Parsons Donald Williams , Lindsay Holly , Wong Tai-Tong , Liu Yen-Lin , Wu Kuo-Sheng , Franson Andrea T. , Hwang Eugene , Aguilar-Bonilla Ana , Cheng Sylvia , Cacciotti Chantel , Massimino Maura , Schiavello Elisabetta , Wood Paul , Hoffman Lindsey M. , Cappellano Andréa , Lassaletta Alvaro , Van Damme An , Llort Anna , Gerber Nicolas U. , Spalato Ceruso Mariella , Bendel Anne E. , Skrypek Maggie , Hamideh Dima , Mushtaq Naureen , Walter Andrew , Jabado Nada , Alsahlawi Aysha , Farmer Jean-Pierre , Coleman Christina , Mueller Sabine , Mazewski Claire , Aguilera Dolly , Robison Nathan J. , O’Halloran Katrina , Abbou Samuel , Berlanga Pablo , Geoerger Birgit , Øra Ingrid , Moertel Christopher L. , Razis Evangelia D. , Vernadou Anastasia , Ducray François , Bronnimann Charlotte , Seizeur Romuald , Clarke Matthew , Resnick Adam C. , Alves Mélanie , Jones Chris , Doz François , Laetsch Theodore W. , Perreault Sébastien
Published: February 2025

Supplementary Table S3. Survival outcome.
Supplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Authors: Lamoureux Audrey-Anne , Fisher Michael J. , Lemelle Lauriane , Pfaff Elke , Amir-Yazdani Pouneh , Kramm Christof , De Wilde Bram , Kazanowska Bernarda , Hutter Caroline , Pfister Stefan M. , Sturm Dominik , Jones David T.W. , Orbach Daniel , Pierron Gaëlle , Raskin Scott , Drilon Alexander , Diamond Eli L. , Harada Guilherme , Zapotocky Michal , Zamecnik Josef , Krskova Lenka , Ellezam Benjamin , Weil Alexander G. , Venne Dominic , Barritault Marc , Leblond Pierre , Coltin Hallie , Hammad Rawan , Tabori Uri , Hawkins Cynthia , Hansford Jordan R. , Meyran Deborah , Erker Craig , McFadden Kathryn , Sato Mariko , Gottardo Nicholas G. , Dholaria Hetal , Nørøxe Dorte Schou , Goto Hiroaki , Ziegler David S. , Lin Frank Y. , Parsons Donald Williams , Lindsay Holly , Wong Tai-Tong , Liu Yen-Lin , Wu Kuo-Sheng , Franson Andrea T. , Hwang Eugene , Aguilar-Bonilla Ana , Cheng Sylvia , Cacciotti Chantel , Massimino Maura , Schiavello Elisabetta , Wood Paul , Hoffman Lindsey M. , Cappellano Andréa , Lassaletta Alvaro , Van Damme An , Llort Anna , Gerber Nicolas U. , Spalato Ceruso Mariella , Bendel Anne E. , Skrypek Maggie , Hamideh Dima , Mushtaq Naureen , Walter Andrew , Jabado Nada , Alsahlawi Aysha , Farmer Jean-Pierre , Coleman Christina , Mueller Sabine , Mazewski Claire , Aguilera Dolly , Robison Nathan J. , O’Halloran Katrina , Abbou Samuel , Berlanga Pablo , Geoerger Birgit , Øra Ingrid , Moertel Christopher L. , Razis Evangelia D. , Vernadou Anastasia , Ducray François , Bronnimann Charlotte , Seizeur Romuald , Clarke Matthew , Resnick Adam C. , Alves Mélanie , Jones Chris , Doz François , Laetsch Theodore W. , Perreault Sébastien
Published: February 2025

Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.
Supplementary Table 1 from Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death
Authors: Cabibbo Giuseppe , Celsa Ciro , Battaglia Salvatore , Enea Marco , Di Maria Gabriele , Grova Alessandro , Ciccia Roberta , Manfredi Giulia F. , Iavarone Massimo , Vogel Arndt , Singal Amit G. , Reig Maria , Pinato David J. , Cammà Calogero
Published: February 2025

Supplementary Table 1. Representativeness of Study Participants.
Supplementary Figure S1 from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Authors: Mastrolonardo Eric V. , Nunes Kathryn L. , Llerena Pablo , Nikitina Anastasia , Sobol Anastasia , Scott E. Reilly , Tuluc Madalina , Davitt Christopher J.H. , Scher Jessica , Tekumalla Sruti , Mann Derek , Henao Camilo , Jegede Victor , Gargano Stacey , Harshyne Larry A. , Alnemri Angela , Tyshevich Andrey , Kushnarev Vladimir , Chasse Madison , Sookiasian Danielle , Axelrod Rita , Zhan Tingting , Leiby Benjamin E. , Old Matthew , Seim Nolan , Mahoney My G. , Martinez-Outschoorn Ubaldo , Cognetti David M. , Curry Joseph M. , Prendergast George , Argiris Athanassios , South Andrew P. , Linnenbach Alban J. , Johnson Jennifer M. , Luginbuhl Adam J.
Published: February 2025

Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site (yellow) and lymph nodes (purple), stratifed by treatment arm.
Table 1 from Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer
Authors: Altan Mehmet , Lopes Gilberto , Hiltermann T. Jeroen N. , Govindan Ramaswamy , Villaruz Liza C. , Calvo Emiliano , Edelman Martin J. , Furqan Muhammad , Neal Joel , Felip Enriqueta , Carlisle Jennifer W. , Heymach John V. , O’Cearbhaill Róisín Eilish , Zauderer Marjorie , Chisamore Michael , Corigliano Ellie , Eleftheriadou Ioanna , Zajic Stefan , Jenkins Ben , Goodison Sophia , Suchindran Sunil , Ramos-Hernandez Natalia , Tarek Nidale , Schoenfeld Adam J.
Published: February 2025

Key comparison overview of single- and multiarm lete-cel NSCLC trials.
Supplementary Table S3 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Authors: Johnson Faye M. , O’Hara Madison P. , Yapindi Lacin , Jiang Peixin , Tran Hai T. , Reuben Alexandre , Xiao Weihong , Gillison Maura L. , Sun Xiaowen , Khalaf Alexander , Lee J. Jack , Sastry Jagannadha K. , Ghosh Soma
Published: February 2025

Supplementary Table S3. Representativeness of Study Participants.
Supplementary Table S2 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Authors: Johnson Faye M. , O’Hara Madison P. , Yapindi Lacin , Jiang Peixin , Tran Hai T. , Reuben Alexandre , Xiao Weihong , Gillison Maura L. , Sun Xiaowen , Khalaf Alexander , Lee J. Jack , Sastry Jagannadha K. , Ghosh Soma
Published: February 2025

Supplementary Table S2. Patient characteristics.
Supplementary Figure S7 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Authors: Johnson Faye M. , O’Hara Madison P. , Yapindi Lacin , Jiang Peixin , Tran Hai T. , Reuben Alexandre , Xiao Weihong , Gillison Maura L. , Sun Xiaowen , Khalaf Alexander , Lee J. Jack , Sastry Jagannadha K. , Ghosh Soma
Published: February 2025

Supplementary Figure S7. Flow cytometry analyses of circulating lymphocyte subsets in patients with acquired resistance (AR, n=8) or de novo resistance (DR, n=4) to prior anti-PD1 immunotherapy.
Supplementary Figure S5 from Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas
Authors: Johnson Faye M. , O’Hara Madison P. , Yapindi Lacin , Jiang Peixin , Tran Hai T. , Reuben Alexandre , Xiao Weihong , Gillison Maura L. , Sun Xiaowen , Khalaf Alexander , Lee J. Jack , Sastry Jagannadha K. , Ghosh Soma
Published: February 2025

Supplementary Figure S5. Flow cytometric analysis of PBMCs isolated from blood samples collected at baseline from the patients with PD or SD.
Supplementary Table S6 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Authors: Mamidi Murali K. , Sinha Sutapa , Mendez Mariana T. , Sanyal Tapojyoti , Mahmud Hasan , Kay Neil E. , Gupta Mamta , Xu Chao , Vesely Sara K. , Mukherjee Priyabrata , Holter Chakrabarty Jennifer , Ghosh Asish K.
Published: February 2025

Supplementary Table S6. Target genes of the NF-kB pathway.
Supplementary Figure S1 from Aberrantly Expressed Mitochondrial Lipid Kinase, AGK, Activates JAK2–Histone H3 Axis and BCR Signal: A Mechanistic Study with Implication in CLL Therapy
Authors: Mamidi Murali K. , Sinha Sutapa , Mendez Mariana T. , Sanyal Tapojyoti , Mahmud Hasan , Kay Neil E. , Gupta Mamta , Xu Chao , Vesely Sara K. , Mukherjee Priyabrata , Holter Chakrabarty Jennifer , Ghosh Asish K.
Published: February 2025

Supplementary Figure S1. Expression status of JAK1 and JAK3 in CLL cells.
Data from Phase Ib Pharmacodynamic Study of the MNK Inhibitor Tomivosertib (eFT508) Combined With Paclitaxel in Patients With Refractory Metastatic Breast Cancer
Authors: Ferrario Cristiano , Mackey John , Gelmon Karen A. , Levasseur Nathalie , Sorensen Poul H. , Oo Htoo Zarni , Negri Gian L. , Tse Veronica W.L. , Spencer Sandra E. , Cheng Grace , Morin Gregg B. , del Rincon Sonia , Cotechini Tiziana , Gonçalves Christophe , Hindmarch Charles C.T. , Miller Wilson H. , Amiri Mehdi , Basiri Tayebeh , Villareal-Corpuz Victor , Sperry Sam , Gregorczyk Kevin , Spera Gonzalo , Sonenberg Nahum , Pollak Michael
Published: February 2025

AbstractPurpose:
Preclinical data motivate clinical evaluation of inhibitors of MAPK-interacting kinases 1 and 2 (MNK1/2). We conducted a phase 1b clinical trial to study target engagement and safety of tomivosertib, a MNK1/2 inhibitor, alone and in combination with paclitaxel.
Patients and Methods:
Eligible patients had metastatic breast cancer resistant to standard-of-care treatments. Biopsies were obtained at baseline and during treatment with tomivosertib, and then tomivosertib was continued with the addition of paclitaxel until disease progression or toxicity. Serum drug levels were measured, and pharmacodynamic endpoints included IHC, proteomics, translatomics, and imaging mass cytometry.
Results:
Tomivosertib alone and in combination with paclitaxel was well tolerated. There was no pharmacokinetic interaction between the drugs. We observed a clear reduction in phosphorylation of eIF4E at S209, a major substrate of MNK1/2, and identified tomivosertib-induced perturbations in the proteome, translatome, and cellular populations of biopsied metastatic breast cancer tissue.
Conclusions:
We conclude that tomivosertib effectively inhibits MNK1/2 activity in metastatic breast cancer tissue and that it can safely be combined with paclitaxel in future phase II studies. We demonstrate feasibility of using proteomic profiles, translatomic profiles, and spatial distribution of immune cell infiltrates for clinical pharmacodynamic studies.
Data from Response-Adaptive Surgical Timing in Neoadjuvant Immunotherapy Demonstrates Enhanced Pathologic Treatment Response in Head and Neck Squamous Cell Carcinoma
Authors: Mastrolonardo Eric V. , Nunes Kathryn L. , Llerena Pablo , Nikitina Anastasia , Sobol Anastasia , Scott E. Reilly , Tuluc Madalina , Davitt Christopher J.H. , Scher Jessica , Tekumalla Sruti , Mann Derek , Henao Camilo , Jegede Victor , Gargano Stacey , Harshyne Larry A. , Alnemri Angela , Tyshevich Andrey , Kushnarev Vladimir , Chasse Madison , Sookiasian Danielle , Axelrod Rita , Zhan Tingting , Leiby Benjamin E. , Old Matthew , Seim Nolan , Mahoney My G. , Martinez-Outschoorn Ubaldo , Cognetti David M. , Curry Joseph M. , Prendergast George , Argiris Athanassios , South Andrew P. , Linnenbach Alban J. , Johnson Jennifer M. , Luginbuhl Adam J.
Published: February 2025

AbstractPurpose:
We evaluated whether indoleamine 2,3-dioxygenase (IDO1) inhibitor (IDOi) BMS986205 + PD-1 inhibitor nivolumab enhanced T-cell activity and augmented immune-mediated antitumor responses in untreated, resectable head and neck squamous cell carcinoma (HNSCC). We employed response-adaptive surgical timing to identify responders to immunotherapy and enhance their response.
Patients and Methods:
Patients with HNSCC were 3:1 randomized to receive nivolumab with or without BMS986205 orally daily (NCT03854032). In the combination arm, BMS986205 was initiated 7 days prior to nivolumab. Patients were stratified by human papillomavirus (HPV) status. Response-adaptive surgical timing involved response assessment by radiographic criteria 4 weeks after treatment with nivolumab in both arms. Nonresponders underwent surgical resection, whereas responders received 4 more weeks of randomized therapy before surgery. Biomarker analysis utilized pathologic treatment response (pTR) and RNA sequencing.
Results:
Forty-two patients were enrolled, and the addition of IDOi to nivolumab did not result in greater rate of radiographic response (P = 0.909). Treatment was well tolerated, with only 2 (5%) patients experiencing grade 3 immune-related adverse events. The addition of IDOi augmented rates of pTR in patients with high baseline IDO1 RNA expression (P < 0.05). Response-adaptive surgical timing demonstrated reliability in differentiating pathologic responders versus nonresponders (P = 0.009). A pretreatment NK cell signature, PD-L1 status, and IFN-γ expression in the HPV− cohort correlated with response. The HPV+ cohort found B-cell and cancer-associated fibroblast signatures predictive of response/nonresponse.
Conclusions:
Response-adaptive surgical timing enhanced treatment response. IDOi BMS986205 augmented pTR in patients with high IDO1 expression in baseline samples, indicating a need for identifying and targeting resistant nodes to immunotherapy. HPV status–dependent signatures predicting response to immunotherapy in HNSCC warrant further study.
Supplementary Table S1 from Roles of Necroptosis, Apoptosis, and Inflammation in Colorectal Carcinogenesis: A Longitudinal Human Study
Authors: Su Timothy , Zhu Xiangzhu , Li Yong , Yu Chang , Deng Xinqing , Shubin Eugene , Hou Lifang , Zhao Jing , Fan Lei , Zhang Heping , Murff Harvey J. , Ness Reid M. , Shrubsole Martha J. , Dai Qi
Published: February 2025

Supplementary Table S1: Adjusted odds ratios with 95% confidence interval for the expression of biomarkers and risk of metachronous polyp, results from the PPCCT
Supplementary Figure S3 from Roles of Necroptosis, Apoptosis, and Inflammation in Colorectal Carcinogenesis: A Longitudinal Human Study
Authors: Su Timothy , Zhu Xiangzhu , Li Yong , Yu Chang , Deng Xinqing , Shubin Eugene , Hou Lifang , Zhao Jing , Fan Lei , Zhang Heping , Murff Harvey J. , Ness Reid M. , Shrubsole Martha J. , Dai Qi
Published: February 2025

Supplementary Figure S3: Differential expression of biomarkers in rectal biopsy samples
Supplementary Figure S2 from Roles of Necroptosis, Apoptosis, and Inflammation in Colorectal Carcinogenesis: A Longitudinal Human Study
Authors: Su Timothy , Zhu Xiangzhu , Li Yong , Yu Chang , Deng Xinqing , Shubin Eugene , Hou Lifang , Zhao Jing , Fan Lei , Zhang Heping , Murff Harvey J. , Ness Reid M. , Shrubsole Martha J. , Dai Qi
Published: February 2025

Supplementary Figure S2: Validation and optimization of TUNEL staining
Supplemental Figure 2 from Metabolic Phenotype and Risk of Obesity-Related Cancers in the Women’s Health Initiative
Authors: Karra Prasoona , Hardikar Sheetal , Winn Maci , Anderson Garnet L. , Haaland Benjamin , Shadyab Aladdin H. , Neuhouser Marian L. , Seguin-Fowler Rebecca A. , Thomson Cynthia A. , Coday Mace , Wactawski-Wende Jean , Stefanick Marcia L. , Zhang Xiaochen , Cheng Ting-Yuan David , Karanth Shama , Sun Yangbo , Saquib Nazmus , Pichardo Margaret S. , Jung Su Yon , Tabung Fred K. , Summers Scott A. , Holland William L. , Jalili Thunder , Gunter Marc J. , Playdon Mary C.
Published: February 2025

Supplemental Figure 2. Directed Acyclic Graph (DAG). Directed Acyclic Graph (DAG) illustrating potential causal relationships among covariates, exposure, and outcome measures in this study.
Table S1 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Authors: Phung Shee Kwan , Zorko Nicholas A. , Soignier Yvette , Waller Rhett L. , Shackelford Madison , Walker Joshua T. , Nelson Trygve D. , Selleck Carly , Bendzick Laura E. , Kotz Laura E. , Kile Quinlan M. , Bozicevich Asha J. , Miller Sarah E. , Khaw Melissa , Shetty Mihir , Hinderlie Peter , Ehrhardt Michael , Li Yingming , Luo Xianghua , Dehm Scott M. , Antonarakis Emmanuel S. , Kennedy Philippa R. , Miller Jeffrey S. , Felices Martin
Published: February 2025

Reagent list for time-of-flight mass cytometry (CyTOF).
Figure S9 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Authors: Phung Shee Kwan , Zorko Nicholas A. , Soignier Yvette , Waller Rhett L. , Shackelford Madison , Walker Joshua T. , Nelson Trygve D. , Selleck Carly , Bendzick Laura E. , Kotz Laura E. , Kile Quinlan M. , Bozicevich Asha J. , Miller Sarah E. , Khaw Melissa , Shetty Mihir , Hinderlie Peter , Ehrhardt Michael , Li Yingming , Luo Xianghua , Dehm Scott M. , Antonarakis Emmanuel S. , Kennedy Philippa R. , Miller Jeffrey S. , Felices Martin
Published: February 2025

PSMA TriKE testing against patient-derived xenograft (PDX).
Figure S2 from A PSMA-Targeted Tri-Specific Killer Engager Enhances NK Cell Cytotoxicity against Prostate Cancer
Authors: Phung Shee Kwan , Zorko Nicholas A. , Soignier Yvette , Waller Rhett L. , Shackelford Madison , Walker Joshua T. , Nelson Trygve D. , Selleck Carly , Bendzick Laura E. , Kotz Laura E. , Kile Quinlan M. , Bozicevich Asha J. , Miller Sarah E. , Khaw Melissa , Shetty Mihir , Hinderlie Peter , Ehrhardt Michael , Li Yingming , Luo Xianghua , Dehm Scott M. , Antonarakis Emmanuel S. , Kennedy Philippa R. , Miller Jeffrey S. , Felices Martin
Published: February 2025

Calculations of equifunctional dose of IL15 compared to PSMA TriKE.
Table S4 from Setdb1 Loss Induces Type I Interferons and Immune Clearance of Melanoma
Authors: McGeary Meaghan K. , Damsky William , Daniels Andrew J. , Lang Sabine M. , Xu Qingji , Song Eric , Huet-Calderwood Clotilde , Lou Hua Jane , Paradkar Sateja , Micevic Goran , Kaech Susan M. , Calderwood David A. , Turk Benjamin E. , Yan Qin , Iwasaki Akiko , Bosenberg Marcus W.
Published: February 2025

Differential expression of SKO vs YRG cells ± IFNAR blockade by RNAseq.
Figure S4 from Combination CXCR4 and PD-1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma
Authors: Morita Satoru , Lei Pin-Ji , Shigeta Kohei , Ando Tomofumi , Kobayashi Tatsuya , Kikuchi Hiroto , Matsui Aya , Huang Peigen , Pittet Mikael J. , Duda Dan G.
Published: February 2025

Supplementary Figure S4
Figure S8 from TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids
Authors: Sun Yi , Maggs Luke , Panda Apekshya , Wright Samuel J. , Cicerchia Angelina M. , Jenney Anne , Perricone Matthew D. , Mills Caitlin E. , Cattaneo Giulia , Ventin Marco , Chen Feng , Rasmussen Martin Q. , Miranda Alex , Revach Or-Yam , Fang Jacy , Fu Amina , Bowling Peter J. , Sharova Tatyana , Lawless Aleigha , Sorger Peter K. , Bardeesy Nabeel , Wang Xinhui , Flaherty Keith T. , Boland Genevieve M. , Mehta Arnav , Sade-Feldman Moshe , Ferrone Cristina R. , Jenkins Russell W.
Published: February 2025

Supplemental Figure S8 | Supporting data that targeting TBK1 prevents CAR-T cell dysfunction.
Supplementary Table S4 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation
Authors: Cho Nam Woo , Guldberg Sophia M. , Nabet Barzin Y. , Yu Jie Zeng , Kim Eun Ji , Hiam-Galvez Kamir J. , Yee Jacqueline L. , DeBarge Rachel , Tenvooren Iliana , Ashitey Naa Asheley , Lynce Filipa , Dillon Deborah A. , Rosenbluth Jennifer M. , Spitzer Matthew H.
Published: February 2025

Supplementary Data Table S4
Supplementary Figure S7 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation
Authors: Cho Nam Woo , Guldberg Sophia M. , Nabet Barzin Y. , Yu Jie Zeng , Kim Eun Ji , Hiam-Galvez Kamir J. , Yee Jacqueline L. , DeBarge Rachel , Tenvooren Iliana , Ashitey Naa Asheley , Lynce Filipa , Dillon Deborah A. , Rosenbluth Jennifer M. , Spitzer Matthew H.
Published: February 2025

Supplementary Data Figure S7
Supplementary Figure S5 from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation
Authors: Cho Nam Woo , Guldberg Sophia M. , Nabet Barzin Y. , Yu Jie Zeng , Kim Eun Ji , Hiam-Galvez Kamir J. , Yee Jacqueline L. , DeBarge Rachel , Tenvooren Iliana , Ashitey Naa Asheley , Lynce Filipa , Dillon Deborah A. , Rosenbluth Jennifer M. , Spitzer Matthew H.
Published: February 2025

Supplementary Data Figure S5
Table S3 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
Authors: Dong Shunli , Ye Cong , Li Bin , Lv Fanglin , Zhang Lu , Yang Shumin , Wang Fang , Zhu Mingxian , Zhou Mingxuan , Guo Fanfan , Li Zhenyun , Peng Lei , Ji Cheng , Lu Xialiang , Cheng Yan , Ren Xingcong , Chen Youguo , Zhou Jinhua , Yang Jinming , Zhang Yi
Published: February 2025

Table S3. Gene expression matrix of TCGA-OV cohort
Supplementary Figure S6 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
Authors: Dong Shunli , Ye Cong , Li Bin , Lv Fanglin , Zhang Lu , Yang Shumin , Wang Fang , Zhu Mingxian , Zhou Mingxuan , Guo Fanfan , Li Zhenyun , Peng Lei , Ji Cheng , Lu Xialiang , Cheng Yan , Ren Xingcong , Chen Youguo , Zhou Jinhua , Yang Jinming , Zhang Yi
Published: February 2025

Figure S6. KEGG pathway and GO (Gene Ontology) term analysis of cytokine antibody microarray.
Supplementary Figure S5 from Targeting of Tumoral NAC1 Mitigates Myeloid-Derived Suppressor Cell–Mediated Immunosuppression and Potentiates Anti–PD-1 Therapy in Ovarian Cancer
Authors: Dong Shunli , Ye Cong , Li Bin , Lv Fanglin , Zhang Lu , Yang Shumin , Wang Fang , Zhu Mingxian , Zhou Mingxuan , Guo Fanfan , Li Zhenyun , Peng Lei , Ji Cheng , Lu Xialiang , Cheng Yan , Ren Xingcong , Chen Youguo , Zhou Jinhua , Yang Jinming , Zhang Yi
Published: February 2025

Figure S5. The number of CD45+CD4+ cells and the percentage of CD45+CD4+IFNγ+ cells show slight changes between ID8-Control and ID8-NIC3 subcutaneous tumors.
Supplementary Table S2 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Authors: Hao Yameng , Gkasti Aspasia , Managh Amy J. , Dagher Julien , Sifis Alexandros , Tiron Luca , Chriqui Louis-Emmanuel , Marie Damien N. , De Souza Silva Olga , Christodoulou Michel , Peters Solange , Joyce Johanna A. , Krueger Thorsten , Gonzalez Michel , Abdelnour-Berchtold Etienne , Sempoux Christine , Clerc Daniel , Teixeira-Farinha Hugo , Hübner Martin , Meylan Etienne , Dyson Paul J. , Cavin Sabrina , Perentes Jean Y.
Published: February 2025

Supplementary Table S2: List of antibodies used in the study
Supplementary Figure S6 from Hyperthermic Intrathoracic Chemotherapy Modulates the Immune Microenvironment of Pleural Mesothelioma and Improves the Impact of Dual Immune Checkpoint Inhibition
Authors: Hao Yameng , Gkasti Aspasia , Managh Amy J. , Dagher Julien , Sifis Alexandros , Tiron Luca , Chriqui Louis-Emmanuel , Marie Damien N. , De Souza Silva Olga , Christodoulou Michel , Peters Solange , Joyce Johanna A. , Krueger Thorsten , Gonzalez Michel , Abdelnour-Berchtold Etienne , Sempoux Christine , Clerc Daniel , Teixeira-Farinha Hugo , Hübner Martin , Meylan Etienne , Dyson Paul J. , Cavin Sabrina , Perentes Jean Y.
Published: February 2025

Supplementary Figure S6: Effect of HITOC on PD-1 and CTLA-4 expression by CD4 T cells.
Data from Identification and Phenotypic Characterization of Neoantigen-Specific Cytotoxic CD4+ T Cells in Endometrial Cancer
Authors: Fusagawa Minami , Tokita Serina , Murata Kenji , Mariya Tasuku , Umemoto Mina , Sugita Shintaro , Matsuo Kazuhiko , Hirohashi Yoshihiko , Saito Tsuyoshi , Kanaseki Takayuki , Torigoe Toshihiko
Published: February 2025

Abstract
Tumor-reactive CD4+ T cells often accumulate in the tumor microenvironment (TME) in human cancer, but their functions and roles in antitumor responses remain elusive. Here, we investigated the immunopeptidome of HLA class II–positive (HLA-II+) endometrial cancer with an inflamed TME using a proteogenomic approach. We identified HLA-II neoantigens, one of which induced polyclonal CD4+ tumor-infiltrating lymphocyte responses. We then experimentally demonstrated that neoantigen-specific CD4+ tumor-infiltrating lymphocytes lyse target cells in an HLA-II–dependent manner. Single-cell transcriptomic analysis of the TME coupled with T-cell receptor sequencing revealed the presence of CD4+ T-cell clusters characterized by CXCL13 expression. The CXCL13+ clusters contained two subclusters with distinct cytotoxic gene expression patterns. The identified neoantigen-specific CD4+ T cells were found exclusively in one of the CXCL13+ subclusters characterized by granzyme B and CCL5 expression. These results demonstrate the involvement of tumor-reactive CD4+ T cells with cytotoxic function in immune surveillance of endometrial cancer and reveal their transcriptomic signature.
Data from T Cells Instruct Immune Checkpoint Inhibitor Therapy Resistance in Tumors Responsive to IL1 and TNFα Inflammation
Authors: Cho Nam Woo , Guldberg Sophia M. , Nabet Barzin Y. , Yu Jie Zeng , Kim Eun Ji , Hiam-Galvez Kamir J. , Yee Jacqueline L. , DeBarge Rachel , Tenvooren Iliana , Ashitey Naa Asheley , Lynce Filipa , Dillon Deborah A. , Rosenbluth Jennifer M. , Spitzer Matthew H.
Published: February 2025

Abstract
Resistance to immune checkpoint inhibitors (ICI) is common, even in tumors with T-cell infiltration. We thus investigated consequences of ICI-induced T-cell infiltration in the microenvironment of resistant tumors. T cells and neutrophil numbers increased in ICI-resistant tumors following treatment, in contrast to ICI-responsive tumors. Resistant tumors were distinguished by high expression of IL1 receptor 1, enabling a synergistic response to IL1 and TNFα to induce G-CSF, CXCL1, and CXCL2 via NF-κB signaling, supporting immunosuppressive neutrophil accumulation in tumor. Perturbation of this inflammatory resistance circuit sensitized tumors to ICIs. Paradoxically, T cells drove this resistance circuit via TNFα both in vitro and in vivo. Evidence of this inflammatory resistance circuit and its impact also translated to human cancers. These data support a mechanism of ICI resistance, wherein treatment-induced T-cell activity can drive resistance in tumors responsive to IL1 and TNFα, with important therapeutic implications.
Supplementary Figure 9 from Loss of NF1 Accelerates Uveal and Intradermal Melanoma Tumorigenesis, and Oncogenic GNAQ Transforms Schwann Cells
Authors: Longakit Anne Nathalie , Urtatiz Oscar , Luty Amy , Zhang Christina , Hess Chloe , Yoo Alyssa , Bourget Hannah , Van Raamsdonk Catherine D.
Published: February 2025

Supplementary Figure 9
Supplementary Figure 6 from Loss of NF1 Accelerates Uveal and Intradermal Melanoma Tumorigenesis, and Oncogenic GNAQ Transforms Schwann Cells
Authors: Longakit Anne Nathalie , Urtatiz Oscar , Luty Amy , Zhang Christina , Hess Chloe , Yoo Alyssa , Bourget Hannah , Van Raamsdonk Catherine D.
Published: February 2025

Supplementary Figure 6
Supplementary Figure 1 from Loss of NF1 Accelerates Uveal and Intradermal Melanoma Tumorigenesis, and Oncogenic GNAQ Transforms Schwann Cells
Authors: Longakit Anne Nathalie , Urtatiz Oscar , Luty Amy , Zhang Christina , Hess Chloe , Yoo Alyssa , Bourget Hannah , Van Raamsdonk Catherine D.
Published: February 2025

Supplementary Figure 1
Figure 2 from Loss of NF1 Accelerates Uveal and Intradermal Melanoma Tumorigenesis, and Oncogenic GNAQ Transforms Schwann Cells
Authors: Longakit Anne Nathalie , Urtatiz Oscar , Luty Amy , Zhang Christina , Hess Chloe , Yoo Alyssa , Bourget Hannah , Van Raamsdonk Catherine D.
Published: February 2025

Histology of intradermal melanomas and sparse pigment tumors in mice expressing oncogenic GNAQ. A, 66 weeks after tamoxifen Plp1-creERT/+; R26-fs-GNAQQ209L/+; +/+ mouse (left) with an intradermal melanoma on the neck. The tumor is shown stained with H&E (right). B, 51 weeks after tamoxifen Plp1-creERT/+; R26-fs-GNAQQ209L/+; Nf1flox/+ mouse (left) with an intradermal melanoma on the upper back. The tumor is shown stained with H&E (right). C–F, 61 weeks after tamoxifen Plp1-creERT/+; R26-fs-GNAQQ209L; +/+ mouse (C) with a sparse pigment tumor on the side of the trunk; tumor shown just after removal (D) and sectioned and stained with H&E (E) and the Masson trichrome (F). An area containing both hypocellular and hypercellular regions of the tumor is enlarged in the boxes below. Arrows point to a hypocellular region. G, Close up images of granular mast cells (arrows) in toluidine blue–stained section of a sparse pigment tumor. H, Wavy collagen bundles (arrows) in H&E-stained section of sparse pigment tumor. I, 48 weeks after tamoxifen Plp1-creERT/+; R26-fs-GNAQQ209L; Nf1flox/+ mouse that developed a sparse pigment tumor on the left shoulder (arrow). J, Another sparse pigment tumor from a different Plp1-creERT/+; R26-fs-GNAQQ209L; Nf1flox/+ mouse, cut in half. K and L, The tumor in I was sectioned and stained with H&E (K) and the Masson trichrome (L). Arrows point to hypocellular region. M and N, The mouse in I also had an armpit tumor (arrow). This tumor had nodules with a macroscopic “bag of worms” plexiform appearance (N). O, The Masson trichrome staining of the nodule shown in N, with enlargements of areas of interest. The surrounding muscle and bone are included.
A comparative study of surgery versus radiation therapy on the risk of cardiovascular disease mortality in patients with early-stage non-small cell lung cancer
Authors: Shen Zijian , Gao Guogang , Liu Chuanping , Yu Ge
Published: February 2025

Objective: Non-small cell lung cancer (NSCLC) lung cancer continues to be a substantial issue in public health, and cardiovascular disease (CVD) is also an important cause of death in NSCLC patients. There is a lack of studies comparing the effects of surgery and radiation therapy on the risk of CVD-mortality in patients with early-stage NSCLC. This study planned to compare the effects of surgery alone and radiation therapy alone on the risk of CVD-mortality in patients with early-stage NSCLC.
Methods: In this cohort study, the data of 32896 participants with NSCLC at stage I or stage II in 2010-2015 were retrieved from the surveillance, epidemiology, and end results (SEER) database. The primary endpoint of this study was CVD mortality, indicating patients died of CVDs and the follow-up was ended in 2020. Univariable Cox regression model was applied to identify covariates. The associations of surgery or radiation therapy with CVD-mortality in in patients with early-stage NSCLC were evaluated via univariable and multivariable Cox regression models and Fine-Gray competitive risk model. Hazards ratio (HR) and confidence interval (CI) were computed.
Results: The median follow-up time was 48.00 (17.00, 60.00) months. There were 854 (6.45%) participants died of CVD in the radiation therapy group and 729 (5.35%) participants died of CVD in the surgery group. After adjusting for confounding factors, the elevated risk of CVD mortality in patients with early-stage NSCLC was observed in patients receiving radiation therapy compared to those receiving surgery (HR=2.33, 95%CI: 2.02-2.69). In the competing risk model, the risk of CVD mortality in patients with early-stage NSCLC was also increased in patients receiving radiation therapy (HR=1.37, 95%CI: 1.2.6-1.55). In the PSM group, the risk of CVD mortality in patients with early-stage NSCLC was also increased in patients who underwent radiation therapy (HR=2.62, 95%CI: 2.12-3.24). Subgroup analysis also revealed that radiation therapy was correlated with increased risk of CVD mortality in NSCLC patients with tumor size ≥50 mm or <50 mm, the original primary site in the left or right, histologic types of squamous cell NSCLC or adenocarcinoma NSCLC, stage I and II, and patients ≥ 65 years or < 65 years.
Conclusions: Radiation therapy was associated with elevated risk of CVD mortality compared to surgery in patients with early-stage NSCLC.
Stereotactic Radiosurgery vs. Neuroablative Techniques for Medically Refractory Trigeminal Neuralgia: A Systematic Review and Meta Analysis of Outcomes
Authors: Akkara Yash , Singh Jolene Marie , Thorne Lewis , Hill Ciaran Scott
Published: February 2025

Background
There is a lack of evidence to guide the choice between stereotactic radiosurgery (SRS) and neuroablative procedures for patients with medically refractory trigeminal neuralgia (TN). This meta-analysis aims to identify the outcomes of these interventions for TN.

Methods
Studies identified through PubMed, MEDLINE, and Embase, were cohort studies or clinical trials, had ≥20 participants, and had a ≥12-month follow-up. All participants were ≥16 years old and had primary refractory TN. Studies reported outcomes using the Barrow Neurological Institute (BNI) scale. The Shapiro-Wilk test, Mann-Whitney U test, two-tailed T Test, Spearman’s R, and ANCOVA were used to test statistical significance. Screening was done according to PRISMA guidelines. Bias assessment was according to the Newcastle-Ottawa Scale.

Results
3288 patients from 37 studies were included (2537 SRS, 751 neuroablative). Overall reporting of BNI I, II, III, IV, and V was 36.0%, 17.4%, 23.9%, 11.7%, and 10.9% respectively in the SRS cohort, and 63.6%, 10.4%, 11.1%, 7.3%, and 7.6% respectively in the neuroablative cohort (p<0.0001). Recurrence was 41.6% in the SRS cohort and 22.5% in the neuroablative cohort (p<0.001). The neuroablative cohort reported significantly higher rates of hypoesthesia (18.6% vs. 50.5%, p<0.0001), and minor (19.6% vs. 2.2%, p<0.0001) and major (3.4% vs. 1.3%, p<0.001) adverse effects compared to SRS.

Conclusions
The findings suggest improved pain relief and reduced recurrence with neuroablative procedures compared to SRS, albeit conferring a higher rate of adverse effects. Neuroablative techniques may be more appropriate for patients with medically refractory TN who are unsuitable for microvascular decompression.
Concomitant Mosaic Turner Syndrome and Congenital Adrenal Hyperplasia in one of three patients of USP9X variant-associated Autism Spectrum Disorder
Authors: Güleç Ahmet , Gerik-Celebi Hamide Betul , Demiral Meliha
Published: February 2025

Introduction: X-Linked Intellectual Developmental Disorder 99 (XLID99) is a rare neurodevelopmental disorder associated with mutations in the USP9X gene. This study reports on three patients diagnosed with autism spectrum disorder (ASD), highlighting novel genetic findings.
Case Presentation: Among the three patients, two male siblings exhibited a novel USP9X gene missense variant, while the third, a female, presented a unique deletion of the USP9X gene alongside adrenal insufficiency and mosaic Turner syndrome. This variant has not been reported in public databases and may influence ASD development.
Conclusion: This report documents the first instance of a triple diagnosis of XLID99, Turner syndrome, and congenital adrenal hyperplasia. Findings underline the significance of genetic evaluation in ASD for identifying rare and complex diagnoses.
As transformações no mundo do trabalho e o futuro do seguro-desemprego no Brasil
Authors: Chahad José Paulo Zeetano
Published: February 2025

This paper deals with the Brazilian unemployment insurance system in relation to the transformations taking place in the labor market, as well as to the need to integrate this instrument to other labor related public policies. Based on the international experience, a consolidation ofthe Public Employment System is proposed, following the lines of Convention number 88, of the International Labor Organization. The system must integrate all government actions needed to improve the work of the unemployment insurance mechanism. It must take into account the operating parameters determined by the market, as well as be submitted to continuous performance evaluation, in a way as to improve efficiency and efficacy in labor market.
Teste cardiopulmonar em exoesqueleto para marcha robotizada em esteira rolante com suspensão do peso corporal: uma opção para avaliação de pessoas com tetraplegia - relato de caso
Authors: Sugawara André Tadeu , Yazbek Junior Paulo , Matheus Denise , Battistella Linamara Rizzo
Published: February 2025

The life expectancy of people with spinal cord injury (SCI) has increased. Ageing has greater exposure to risk factors, increasing the morbidity of non-communicable diseases, especially cardiovascular. Objective: To describe the use of a robotic exoskeleton for robotic walking on a treadmill with body weight support to evaluate patients with tetraplegia during a cardiopulmonary exercise test (CPET). Case presentation: 55-year-old woman with tetraplegia C4 AIS B, unable to walk, she underwent CPET to determine ventilatory training Threshold and energy expenditure. A portable ergospirometry system was used to measure maximum oxygen consumption (VO2 Max) during the test. Results: During CPET, the electrocardiographic tracing did not indicate ischemic changes, remaining in sinus rhythm. There was an increase in heart rate during physical exertion, but gas exchange was adequate, indicating an increase in the metabolic demand supplied through respiratory adaptations. Discussion: Patients with tetraplegia often have altered ventilation patterns that can limit their aerobic capacity. Using the exoskeleton for both assessment and training simplifies the treatment, reducing displacements and improving the safety and comparability of results. Conclusion: The use of the exoskeleton for CPET offers an integrated effective approach for SCI patients, replicating the naturalistic activity of walking during cardiovascular and rehabilitation training.
Classificação Internacional de Funcionalidade, Incapacidade e Saúde como tecnologia em cuidado da saúde do trabalhador: uma revisão integrativa
Authors: Krug Suzane Beatriz Franz , Bienert Ana Carolina , Freitas Luci Helen Alvez , Martins Bruna Rezende , Pappen Morgana , Linhares Edna Garcia , Dubow Camila
Published: February 2025

A Classificação Internacional de Funcionalidade, Incapacidade e Saúde (CIF) é considerada uma ferramenta de cuidado em saúde, com perspectiva de assistência abrangente e multiprofissional, considerando capacidades funcionais e engajamento social dos indivíduos. Objetivo: Identificar e analisar a utilização da CIF como tecnologia de cuidado na atenção à saúde do trabalhador. Método: Revisão integrativa da literatura. Buscou-se, com quatro descritores em português, inglês e espanhol, artigos nas bases de dados LILACS, Pubmed e SciELO, publicados entre 2013 e 2023, seguindo a recomendação PRISMA. Resultados: Do total de 77 artigos, a seleção finalizou em 12 artigos. Seguindo a Análise de Conteúdo, os resultados foram divididos e analisados em dois campos temáticos, que apontaram o uso da CIF em diferentes situações de adoecimento e com diversos segmentos de trabalhadores. O outro campo temático indicou a implementação de escalas e instrumentos baseados na CIF, aplicados à saúde mental, reabilitação, trabalhadores com deficiência e doença clínica crônica, identificando funcionalidades, barreiras e facilitadores na manutenção do emprego e no ambiente de trabalho. Conclusão: a CIF constitui-se como tecnologia de cuidado em saúde do trabalhador, aprimorando a assistência e também os processos de trabalho dos profissionais que atendem os trabalhadores nos mais diversos serviços.
Relação entre o uso das praças e a forma urbana em Palmas (TO)
Authors: Oliveira Lucimara Albieri de , Brzezinski Andressa Kucla da Rocha
Published: February 2025

Este artigo, fruto de uma dissertação de mestrado, explora a relação entre a forma urbana e o uso das praças em Palmas, cidade planejada em 1989 para ser a capital do Tocantins. O estudo visa compreender o grau de interferência do desenho urbano no uso das praças por moradores e visitantes, identificando padrões de interação social. A pesquisa, de caráter exploratório-descritivo, categorizou as praças da área projetada de Palmas segundo suas características formais e locacionais. Em seguida, realizou-se um estudo comparativo entre as diferentes categorias, suscitando interrelações entre tais características e os padrões de uso pela população. Os resultados indicam que a eficácia dos espaços públicos em promover integração social e qualidade de vida depende da localização e da conexão com o entorno, sugerindo que o planejamento urbano deve priorizar a inserção, a qualificação, a acessibilidade e a conectividade no tecido urbano.
Fictional projections, anticipated catastrophes: the power of climate fiction in addressing the environmental crisis
Authors: Guimarães Mariana Pereira , Rodrigues Hermano Luz
Published: February 2025

Climate fiction has become an increasingly relevant genre for exploring the environmental challenges facing our world today. This paper reflects on the absence of social and political engagement with the environmental crisis and the potential role of climate fiction to spark empathy and inspire action towards the issue. Furthermore, the paper examines three works of climate fiction—The Netherlands Lives with Water by Jim Shepard, Venice Drowned by Kim Stanley Robinson, and The Living Mountain by Amitav Ghosh. Through the lens of these narratives, the paper explores how fiction can transcend the limitations of traditional scientific discourse by engaging readers emotionally and imaginatively. These stories detail ways in which to provide a more relatable and impactful means of communicating the urgency of the crisis. Ultimately, it argues for the value of climate fiction as a critical tool in motivating climate action.
Preterm Birth and Cardiometabolic Health Trajectories From Birth to Adulthood: The Avon Longitudinal Study of Parents and Children
Authors: Clayton Gemma L. , Howe Laura D. , O'Keeffe Linda M. , Lewandowski Adam J. , Lawlor Deborah A. , Fraser Abigail
Published: February 2025

Background

Adults who were born prematurely (<37 weeks’ gestation) are at increased cardiovascular disease risk, but it is unclear when in the life course this risk emerges. Our aim was to compare trajectories of multiple cardiometabolic risk factors from childhood to early adulthood between those who had and had not been born preterm.

Methods and Results

Multilevel models were used to compare trajectories from early childhood (<9 years) to age 25 years of body mass index, fat and lean mass, systolic and diastolic blood pressure, lipids, glucose, and insulin, between individuals born preterm (N=311–676; range, 25–36 weeks’ gestation) and term (N=4973–10 534) in a UK birth cohort study. We also investigated gestational age as a continuum. In children born preterm (versus term), systolic and diastolic blood pressures were higher at age 7 years (mean predicted differences, 0.7 [95% CI, −0.2 to 1.6] mm Hg and 0.6 [95% CI, −0.04 to 1.3] mm Hg, respectively). By age 18 years, the difference in systolic blood pressure persisted (1.9 [95% CI, 0.8–3.1] mm Hg) and in diastolic blood pressure (0.1 [95% CI, −0.7 to 1.0 mm Hg]) disappeared. By age 25 years, this difference in systolic blood pressure began to attenuate towards the null (0.9 [95% CI, −0.5 to 2.3] mm Hg). Participants born preterm (versus term) had lower body mass index between ages 7 and 18 years, but by age 25 years, there was no difference. Fat and lean mass trajectories were consistent with body mass index. High‐density lipoprotein cholesterol was higher and triglycerides lower at birth, in those born preterm, but this difference also disappeared by age 25 years. There was no evidence of differences in glucose and insulin.

Conclusions

Few, modest differences in cardiometabolic health were found in those born preterm versus term. All disappeared by age 25 years, except the small difference in systolic blood pressure. Longer follow‐up is needed to establish if and when cardiometabolic health trajectories diverge between these 2 groups.
Association Between the Malnutrition Status and All‐Cause Mortality in Patients With Moderate and Severe Aortic Stenosis: A Prospective Cohort Study
Authors: Li Bingzhen , Zhang Shaozhao , Xu Chaoguang , Huang Mengting , Xiong Zhenyu , Hui Ziwen , Liao Xinxue , Li Jilin , Chen Jianying , Zhuang Xiaodong
Published: February 2025

Background

Malnutrition status is an important predictor of prognosis in patients after aortic valve replacement. However, the prognostic value of malnutrition status in patients with moderate‐to‐severe aortic stenosis is unclear. This study aimed to evaluate the effect of malnutrition on all‐cause mortality in patients with moderate‐to‐severe aortic stenosis using the Patient Controlled Nutritional Status (CONUT) score, nutritional risk index, and prognostic nutritional index.

Methods and Results

A total of 536 patients with moderate‐to‐severe aortic stenosis were selected in the ARISTOTLE (Aortic Valve Diseases Risk Factor Assessment and Prognosis Model Construction) study conducted between January 2013 and December 2022 in 3 academic institutions. Patients were grouped according to different nutritional status assessment methods. CONUT, nutritional risk index, and prognostic nutritional index were calculated at baseline. The primary study outcome was all‐cause mortality. Cox regression was used to assess the association between nutritional status and all‐cause mortality. During a median 34.2‐month follow‐up period, a total of 120 (22.4%) patients died. All‐cause mortality was significantly higher in lower prognostic nutritional index, lower nutritional risk index, and higher CONUT groups. Compared with normal nutrition, malnutrition was associated with an increased risk for all‐cause death (adjusted hazard ratio for mild and moderate–severe malnutrition, respectively: 2.82 [95% CI, 1.69–4.71;
P
<0.001] and 3.31 [95% CI, 1.74–6.32;
P
<0.001] for the CONUT).

Conclusions

In patients with moderate or severe aortic stenosis, we found that high CONUT scores, low nutritional risk index scores, and low prognostic nutritional index scores were associated with all‐cause death. The poorer the nutritional status, the greater the risk of malnutrition‐related all‐cause mortality.

Registration

URL: 
https://www.clinicaltrials.gov
; Unique identifier: NCT06069232.